BioSight
Companies
Vanda Pharmaceuticals Inc. logo

VNDA

NASDAQWASHINGTON, DC
Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals develops and commercializes medicines across psychiatry, sleep disorders, neurology, and gastroenterology. The company markets Fanapt for schizophrenia and bipolar disorder, HETLIOZ for sleep-wake disorders, and PONVORY for multiple sclerosis, while advancing candidates like Bysanti (in regulatory review for bipolar and depressive disorders) and Nereus (for motion-induced nausea) toward FDA approval. Vanda operates across both marketed products generating current revenue and pipeline assets in late-stage development.

Price history not yet available for VNDA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar